### The Human Genome and Individualized Medicine

#### David Valle, MD McKusick-Nathans Institute of Genetic Medicine Johns Hopkins University 2 December 2011





dvalle@jhmi.edu

### What is "Individualized Medicine" ??

"At it's most basic, personalized medicine refers to using information about a person's genetic makeup to tailor strategies for the detection, treatment or prevention of disease"

### Francis Collins

Interview published July 17, 2005 in the Boston Globe

## Genetics & medicine, 2011: Some terms \*

- Personal
  - Relating to somebody's private life, intimacy
- Relating to one person, a particular
  Initidididalal
  - A particular person, distinct from others

\* Encarta World English Dictionary, 1999

## Individualized Medicine: Why now?

- Enormous success of modern medicine
  - Prolongation of lifespan
  - Improved quality of life
- Ongoing concerns
  - Many diseases with increasing incidence
  - Unacceptable frequency of adverse events
  - Increasing expense



- Incidence increasing throughout the industrialized world and intertwined with obesity
- Chronic illness with an array of complications
  - ✓ Microvascular
  - ✓ Macrovascular





Suppose a member of your family develops type II diabetes .....

- Would you like to know the prognosis and response to existing treatments for the average patient?
- Or, would you like to know as precisely as possible the specific features, prognosis and response to therapy for your loved one?
- Even better, would you like to know ahead of time, assuming preventative measures were available???

## Medicine of the 20<sup>th</sup> Century

 "Average medicine" – medicine for the average patient (the "classic case" mentality)

#### The "classic case" mentality



## Medicine of the 20<sup>th</sup> Century

 "Average medicine" – medicine for the average patient (the "classic case" mentality)

 "Trial and error medicine" – trying possible treatments sequentially until you find one that works

## Individualized medicine

"The experienced physician knows that no two patients are exactly alike"

"There is no science of the individual, and medicine suffers from a fundamental contradiction: its practice deals with the individual while its theory grasps universals only"

#### **O. Temkin, 1963**

### Not a new idea.....

"The doctor does not treat 'man' except accidentally; he treats Calius or Socrates or someone else... So if someone ...knows the universal without knowing the individuals contained in it, he will often fail in his treatment; for it is the individual who has to be treated"

Each of these individuals has his or her own:

- unique sampling of our species genetic endowment
- unique history of in utero development
- family with its unique constellation of

socio-economic variables

## What has changed ??

 HGP, sequencing technology and appreciation of sequence variation

Whole Genome Sequence (WGS) biology

 Increasing prominence of evolutionary thinking in medicine

- Disease gene identification
- Individual annoma socurances


Valle\_Dec\_2011

## What has changed ??

 HGP, sequencing technology and appreciation of sequence variation

- Whole Genome Sequence (WGS) biology
- Increasing prominence of evolutionary thinking in medicine
- Disease gene identification
- Individual appama sociumas


Valle\_Dec\_2011



#### Valle July 2011

2003

#### What is a gene?



## Some features of the reference genome

	Human	Mouse
	(3.0 Gb)	(2.5 Gb)
Genes (protein coding)	~ 22,000	~ 22,000
known function	~ 75%	~ 75%
exons / transcript	8.7	8.4
total exons "exome"	~ 220,000	~ 210,000
the "exome"	~ 50 Mb (1.5%)	

## DNA Sequence: Are We All the Same ?

- Humans are 99.6% identical at the sequence level
- Evolutionary perspective:
  - *H. sapiens* a young species (100 K yr) with a small founding population (~ 10,000)
  - Similarity with our relatives
    - 70-90% identity with mouse
    - 98.5% identity with chimp



### HapMap : A Database of Human Sequence Variation



#### www.hapmap.org


#### 27 October 2005

## A map of human genome variation from population-scale sequencing

The 1000 Genomes Project Consortium\*

Nature 467: 1061, 2010

- Study ~2,500 individuals from ~50 populations
- Catalog >95% of variants with an allele frequency 1%
  across the genome
- Catalog lower frequency alleles (> 0.1%) in coding sequence



## Sources of Genetic Variation

- Insertions / deletions -"indels" ~10%
- Length polymorphisms STRp 5%
- Single nucleotide polymorphisms (SNPs)
   45%
- Copy number variants (CNVs)
   Recombination
   Inversions

# Single Nucleotide Polymorphisms (SNPs)

- Single base pair variant with both possibilities relatively frequent
  - allele 1  $\dots$  GATCA...
  - allele 2 ... G A G C A ...
- Frequent ~ 1/1000 bp or at least 3 x 10<sup>6</sup> per haploid genome
- Current SNP genotyping platforms score >1 x10<sup>6</sup> SNPs across the genome

## Copy Number Variants (CNVs)



Expose dosage sensitive genes

 For deletions, expose otherwise "normal variation" on the remaining allele

Create "fusion" genes with new functions


Increasing appreciation for human genetic variation

SNPs


> 30 M in our species
 ~ 3 M differences
 between individuals
 CNVs

✓ 3-7 large CNVs/individual
✓ 5-10% have 1 CNV >
100kb

✓ 1-2 % have 1 CNV > 1
 Mb




Valle\_July\_2011



### Human Variation

#### Differ at only ~ 1 / 1000 bp !!




## What has changed ??

 HGP, sequencing technology and appreciation of sequence variation

- Whole Genome Sequence (WGS) biology
- Increasing prominence of evolutionary thinking in medicine
- Disease gene identification
- Individual annoma socurances

Valle\_Dec\_2011

## Whole genome sequences: bridges that connect all biology



## What has changed ??

 HGP, sequencing technology and appreciation of sequence variation

 Whole Genome Sequence (WGS) biology

 Increasing prominence of evolutionary thinking in medicine

Disease gene identification

Individual annoma socurances

Valle\_Dec\_2011

# Evolutionary thinking and medicine\*

Centrality of variation

 Continuity and consequences of natural selection

- Evolvability and systems biology
- Emphasis on integrated biology
- Individuality -- Selection acts on individuals Nesse et al, PNAS, Jan 2010

Valle\_dec\_201<sup>2</sup>

#### Comparative Genomics of Higher Primates

STAR FORMATION A massive protostar unveiled

> CANCER IMMUNOLOGY How tumours dupe T cells

> > AIR POLLUTION China's NO<sub>2</sub> build-up seen from space


NATUREJOBS Membrane proteomics

#### A Draft Sequence of the Neandertal Genome Science 328: 710, 201

Richard E. Green, <sup>1</sup>\*†‡ Johannes Krause, <sup>1</sup>†§ Adrian W. Briggs, <sup>1</sup>†§ Tomislav Maricic, <sup>1</sup>†§ Udo Stenzel, <sup>1</sup>†§ Martin Kircher, <sup>1</sup>†§ Nick Patterson, <sup>2</sup>†§ Heng Li, <sup>2</sup>† Weiwei Zhai, <sup>3</sup>†|| Markus Hsi-Yang Fritz, <sup>4</sup>† Nancy F. Hansen, <sup>5</sup>† Eric Y. Durand, <sup>3</sup>† Anna-Sapfo Malaspinas, <sup>3</sup>† Jeffrey D. Jensen, <sup>6</sup>† Tomas Marques-Bonet, <sup>7,13</sup>† Can Alkan, <sup>7</sup>† Kay Prüfer, <sup>1</sup>† Matthias Meyer, <sup>1</sup>† Hernán A. Burbano, <sup>1</sup>† Jeffrey M. Good, <sup>1,8</sup>† Rigo Schultz, <sup>1</sup> Ayinuer Aximu-Petri, <sup>1</sup> Anne Butthof, <sup>1</sup> Barbara Höber, <sup>1</sup> Barbara Höffner, <sup>1</sup> Madlen Siegemund, <sup>1</sup> Antje Weihmann, <sup>1</sup> Chad Nusbaum, <sup>2</sup> Eric S. Lander, <sup>2</sup> Carsten Russ, <sup>2</sup> Nathaniel Novod, <sup>2</sup> Jason Affourtit, <sup>9</sup> Michael Egholm, <sup>9</sup> Christine Verna, <sup>21</sup> Pavao Rudan, <sup>10</sup> Dejana Brajkovic, <sup>11</sup> Željko Kucan, <sup>10</sup> Ivan Gušic, <sup>10</sup> Vladimir B. Doronichev, <sup>12</sup> Liubov V. Golovanova, <sup>12</sup> Carles Lalueza-Fox, <sup>13</sup> Marco de la Rasilla, <sup>14</sup> Javier Fortea, <sup>14</sup>¶ Antonio Rosas, <sup>15</sup> Ralf W. Schmitz, <sup>16,17</sup> Philip L. F. Johnson, <sup>18</sup>† Evan E. Eichler, <sup>7</sup>† Janiel Falush, <sup>19</sup>† Ewan Birney, <sup>4</sup>† James C. Mullikin, <sup>5</sup>† Montgomery Slatkin, <sup>3</sup>† Rasmus Nielsen, <sup>3</sup>† Janet Kelso, <sup>1</sup>† Michael Lachmann, <sup>1</sup>† David Reich, <sup>2,20</sup>\*† Svante Pääbo<sup>1</sup>\*†

# Some genes with positive selection around the time of divergence:

- THADA energy metab
- DYRK1A cognition
- NRG3 neurodevelopment
- several microRNAs



## What has changed ??

 HGP, sequencing technology and appreciation of sequence variation

 Whole Genome Sequence (WGS) biology


 Increasing prominence of evolutionary thinking in medicine

Disease gene identification

Individual appama socurances


Valle\_Dec\_2011

#### Progress in Disease Gene Identification – Dec 2



### Progress in disease gene identification

- OMIM lists ~2500 disease ger ~15% of tota
- GeneTests lists >1900 diseases with molecular tests
   Growth of Gene
- Molecular cytogenetics



Progress in identifying genes contributing risk for complex traits

#### Online Mendelian Inheritance in Man



#### Online Mendelian Inheritance in Man®

An Online Catalog of Human Genes and Genetic Disorders

Updated 14 November 2011

Search

Sample Searches

Advanced Search: OMIM, Clinical Synopses, OMIM Gene Map







### **Online Mendelian Inheritance in Man**

Marfan Advanced Search: OMIM, Clinical Synopses, OMIM Gene Map Display: Toggle highlight Search History: View, Clear			Sort by: <ul> <li>Relevance</li> <li>Date updated</li> </ul> Retrieve corresponding: gene map clinical synopses		
Result	n: 'Marfan' s: 1 - 10 of 98   Show all   1 2 3 4 5 6 7 8 9 10 Next Last				
1:	* 134797. FIBRILLIN 1; FBN1 Cytogenetic location: 15q21.1, Genomic coordinates (GRCh37): 15:48,700,502 - 48,937,984				
2 :	# 154700. MARFAN SYNDROME; MFS Cytogenetic location: 15q21.1				
3:	# 610380. LOEYS-DIETZ SYNDROME, TYPE 2B; LDS2B Cytogenetic location: 3p24.1				
4 :	# 121050. ARTHROGRYPOSIS, DISTAL, TYPE 9; DA9 Cytogenetic location: 5q23.3				
5:	* 190182. TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE II; TGF Cytogenetic location: 3p24.1, Genomic coordinates (GRCh37): 3:30,647,993 - 30,735,633	BR2			
6 :	# 129600. ECTOPIA LENTIS, ISOLATED, AUTOSOMAL DOMINANT Cytogenetic location: 15q21.1		www.OMIM.org		

### **Online Mendelian Inheritance in Man**

Home   About   Statistics -   Downloads   Help -   External Links   Copyright   Contact Us	
tall stature and dislocated lens	Search Sort by: <ul> <li>Relevance</li> <li>Date updated</li> </ul>
Advanced Search: Online, Chinical Synopses, OMIM Gene Map Display: Toggle highlight Search History: View, Clear	Retrieve corresponding: gene map clinical synopses
Search: 'tall stature and dislocated lens'	

Results: 1 - 10 of 11 | Show all | 1 2 Next Last

1: \* 134797. FIBRILLIN 1; FBN1

Cytogenetic location: 15q21.1, Genomic coordinates (GRCh37): 15:48,700,502 - 48,937,984

#### 2: # 236200. HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY

HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED Cytogenetic locations: 21q22.3


- 3 : # 154700. MARFAN SYNDROME; MFS Cytogenetic location: 15q21.1
- # 268400. ROTHMUND-THOMSON SYNDROME; RTS Cytogenetic location: 8q24.3
- 5 : \* 612570. FIBRILLIN 2; FBN2 Cytogenetic location: 5q23.3 , Genomic coordinates (GRCh37): 5:127,593,600 - 127,873,734
- 6 : \* 120160. COLLAGEN, TYPE I, ALPHA-2; COL1A2 Cytogenetic location: 7q21.3 , Genomic coordinates (GRCh37): 7:94,023,872 - 94,060,543
- 7: # 224690. MEIER-GORLIN SYNDROME 1; MGORS1 Cytogenetic location: 1p32.3



### **Online Mendelian Inheritance in Man**

About   Statistic	s ▼   Downloads   Help ▼   Externa	I Links   Copyright   Contact Us			🔧 Select Language	
stature and dis nced Search: OMIM, ( ch History: View, Clea	Clinical Synopses, OMIM Gene Map Display: To	iggle highlight	Search Sort by: • Re	levance 🔘 Date updated		
Alternative title	ICD+ IARFAN SYNDROME; MFS ternative titles; symbols ARFAN SYNDROME, TYPE I; MFS1					
Location	Phenotype	Phenotype	Gene/Locus	Gene/Locus	Genotype/Phenotype Correlatio Pathogenesis	
15q21.1	Marfan syndrome	MIM number 154700	FBN1	MIM number 134797	Diagnosis	
Clinical Synop	Clinical Management Animal Model					
<b>TEXT</b> A number sign		-	ndrome appear to be due to h	eterozygous mutation in the fibrillin-1	History Clinical Synopsis See Also References Contributors Creation Date Edit History External Links:	
<b>TEXT</b> A number sign	(#) is used with this entry becau	-	ndrome appear to be due to h	eterozygous mutation in the fibrillin-1	History Clinical Synopsis See Also References Contributors Creation Date Edit History	
TEXT A number sign gene (FBN1; 13 Description	(#) is used with this entry becau 4797), which is located on chrom	osome 15q21.1.		eterozygous mutation in the fibrillin-1 riability. The cardinal features occur in	History Clinical Synopsis See Also References Contributors Creation Date Edit History External Links:	
TEXT A number sign gene (FBN1; 13 Description A heritable dis 3 systemsske	(#) is used with this entry becau 4797), which is located on chrom order of fibrous connective tissue letal, ocular, and cardiovascular	osome 15q21.1. e, Marfan syndrome shows strikin	g pleiotropism and clinical var AcKusick, 1979; Pyeritz, 1993)		History Clinical Synopsis See Also References Contributors Creation Date Edit History External Links: Clinical Resources	

## Progress in Disease Gene Identification – Dec 2




## Genome wide association studies

 Agnostic approach that identifies SNP markers enriched in cases as compared to controls

 Identification of causative variants in LD with the marker leads to definition of genes & biological systems involved in the disease of interest

 Understanding pathophysiology increases the opportunity for prevention and/or treatment



Manolio, NEJM 363: 166, 2010


## Published Genome-Wide Associations through 3/2011, 779 published GWA at $p \le 5x10^{-8}$ for 205 traits


NHGRI GWA Catalog www.genome.gov/GWAStudies

#### Some conclusions:

 Many tag genes & systems previously not know to be relevant

- > 80% in regulatory space
- In aggregate, much of heritability remains to






# The problem of poor predictive value

"the risk allele at this SNP confers a risk to individuals that is only 1.2 x greater than those who do not have the risk allele"

- Calculated in populations, applied to individuals
- Biologically naïve



 Need for a biologically – based analytic methods that consider the constellation of variants as well as developmental, environmental and epigenetic variants in a particular individual

Locus & SNP id	Metabolic trait	<b>P</b> value	Relationship between gene function and the associated metabolic traits	Biomedical and pharmaceutical interest
ACADS rs2066938	Butyrylcarnitine/propionylcarnitine	<4.4 ×10 <sup>-305</sup>	Butyrylcarnitine <sup>+</sup> and propionylcarnitine <sup>+</sup> are substrates/products of ACADS	ACADS is a key enzyme in mitochondrial fatty acid β-oxidation
NAT8 rs13391552	N-acetylornithine	5.4 × 10 <sup>-252</sup>	N-acetyltransferase function of NAT8 matches the associating metabolite N-acetylornithine <sup>+</sup>	Association with glomerular filtration and CKD; association of N-acetylornithine <sup>+</sup> with eGFR in this study
FADS1 rs174547	1-arachidonoylglycerophosphoethanolamine/ 1-linoleoylglycerophosphoethanolamine	$8.5 \times 10^{-116}$	FADS1 substrate/product pair ratio arachidonate (20:4n6) <sup>+</sup> /dihomo- linolenate (20:3n3 or n6) <sup>+</sup> is among the top associations	Association with LDL cholesterol, HDL cholesterol and triglycerides, fasting glucose and homeostatic model assessment B (HOMA-B) Crohn's disease and resting heart rate
UGT1A rs887829	Bilirubin (E,E)/oleoylcarnitine	2.9 × 10 <sup>-74</sup>	Bilirubin <sup>+</sup> is a substrate of UGT1A1	Association with <b>hyperbilirubinaemia</b> ; low serum concentrations of bilirubin associate with increased risk of CAD; a SNP in <i>UGT1A1</i> is a pharmacogenetic risk factor for irinotecan toxicity
ACADM rs211718	Hexanoylcarnitine/oleate (18:1n9)	$2.2 \times 10^{-71}$	Hexanoylcarnitine <sup>+</sup> is a substrate of ACADM	ACADM is a key enzyme in mitochondrial fatty acid β-oxidation
OPLAH rs6558295	5-oxoproline	$1.5  imes 10^{-59}$	5-oxoproline <sup>+</sup> is a substrate of 5-oxoprolinase OPLAH	
SCD rs603424	Myristate (14:0)/myristoleate (14:1n5)	2.9 × 10 <sup>-57</sup>	SCD catalyses the $\Delta$ -9-desaturation of fatty acids, such as myristate (14:0) <sup>+</sup> to myristoleate (14:1n5) <sup>+</sup> and palmitate (16:0) <sup>+</sup> to palmitoleate (16:1n7) <sup>+</sup>	Palmitoleate (16:1n7) is a lipokine linking adipose tissue to systemic metabolism
GCKR rs780094	Glucose/mannose	5.5 × 10 <sup>-53</sup>	GCKR has a role in glucose homeostasis; strong association with mannose <sup>+</sup> to glucose <sup>+</sup> ratios matches the gene's function	Association with type 2 diabetes, fasting glucose, fasting insulin; serum uric acid; triglyceride levels; C-reactive protein; serum creatinine (eGFRcrea), Crohn's disease and hypertriglyceridaemia

#### Table 1 | Thirty-seven loci that displayed genome-wide significance in the meta-analysis

## What has changed ??

 HGP, sequencing technology and appreciation of sequence variation

 Whole Genome Sequence (WGS) biology

 Increasing prominence of evolutionary thinking in medicine

Disease gene identification

Individual annoma socurances


Valle\_Dec\_2011

## The Diploid Genome Sequence of an Individual Human

Samuel Levy<sup>1\*</sup>, Granger Sutton<sup>1</sup>, Pauline C. Ng<sup>1</sup>, Lars Feuk<sup>2</sup>, Aaron L. Halpern<sup>1</sup>, Brian P. Walenz<sup>1</sup>, Nelson Axelrod<sup>1</sup>, Jiaqi Huang<sup>1</sup>, Ewen F. Kirkness<sup>1</sup>, Gennady Denisov<sup>1</sup>, Yuan Lin<sup>1</sup>, Jeffrey R. MacDonald<sup>2</sup>, Andy Wing Chun Pang<sup>2</sup>, Mary Shago<sup>2</sup>, Timothy B. Stockwell<sup>1</sup>, Alexia Tsiamouri<sup>1</sup>, Vineet Bafna<sup>3</sup>, Vikas Bansal<sup>3</sup>, Saul A. Kravitz<sup>1</sup>, Dana A. Busam<sup>1</sup>, Karen Y. Beeson<sup>1</sup>, Tina C. McIntosh<sup>1</sup>, Karin A. Remington<sup>1</sup>, Josep F. Abril<sup>4</sup>, John Gill<sup>1</sup>, Jon Borman<sup>1</sup>, Yu-Hui Rogers<sup>1</sup>, Marvin E. Frazier<sup>1</sup>, Stephen W. Scherer<sup>2</sup>, Robert L. Strausberg<sup>1</sup>, J. Craig Venter<sup>1</sup>

1 J. Craig Venter Institute, Rockville, Maryland, United States of America, 2 Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada, 3 Department of Computer Science and Engineering, University of California San Diego, La Jolla, California, United States of America, 4 Genetics Department, Facultat de Biologia, Universitat de Barcelona, Barcelona, Catalonia, Spain

- 4.1 million variants vs. reference sequence including
- 3.2 million SNPS
- ~ 300,000 CNVs
- 90 inversions
- total covers 12.3 MB




What does this all mean for medicine?

Dr. Cerani on rounds, Eugene Smith

## Science of the Individual: Some Consequences for Medicine

- Exposes the pitfalls of typological thinking the classical case mentality
- Confirms physiologic view of disease each individual has their own disease
- Emphasizes the importance of asking:
  - "Why does this patient have this illness at this time?"
- What prevention/treatment best for this individual?



#### 1 Medical geneticist 1 Genetic counselor

#### Clinical assessment incorporating a personal genome

Euan A Ashley, Atul J Butte, Matthew T Wheeler, Rong Chen, Teri E Klein, Frederick E Dewey, Joel T Dudley, Kelly E Ormond, Aleksandra Pavlovic, Alexander A Morgan, Dmitry Pushkarev, Norma F Neff, Louanne Hudgins, Li Gong, Laura M Hodges, Dorit S Berlin, Caroline F Thorn, Katrin Sangkuhl, Joan M Hebert, Mark Woon, Hersh Sagreiya, Ryan Whaley, Joshua W Knowles, Michael F Chou, Joseph V Thakuria, Abraham M Rosenbaum, Alexander Wait Zaranek, George M Church, Henry T Greely, Stephen R Quake, Russ B Altman Lancet 375: 1525, 201

"The explanatory power and path to clinical translation of risk estimates for common variants reported in GWAS remain unclear. ... present analytical methods are insufficient to make genetic data accessible in a clinical context, and the clinical usefulness of these data for individual patients has not been formally assessed. We aim to undertake an integrated analysis of a complete human genome in a Valle July 2011 aliniaal aantayt "

# Going forward: the path to individualized medicine


- Rigorous research basic, translational and clinical
- New technology will greatly accelerate the pace
- Will not be quick but has already begun...
  - Acute lymphoblastic leukemia
  - ✓ Sickle cell disease
  - Glioblastoma multiforme & isocitrate dehydrogenase I (12% of tumors het for\_July\_2011

#### HUMAN GENETICS

#### Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels

Gudmundsson ... Stefansson, Sci Transl Med 2: 62ra92

- ~40% variation in PSA levels is genetic
- Influenced by at least 6 loci
- 3834 men with PSA levels and prostate bx
- Suggests individualized PSA cutoff value (i.e. the population average) too high for some and too low for others



The special case of pharmacogenetics

 Environmental variable well defined in terms of timing and amount


Drug and drug metabolites can be measured

Metabolism often known

Alternatives available

#### SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study Search Collaborative Group, NEJM 359: 789, 20

 Odds ratio for myopathy 4.3 in heterozygotes; 17.4 in homozygotes




Valle\_Jan\_201

# Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance

Dongliang Ge<sup>1</sup>, Jacques Fellay<sup>1</sup>, Alexander J. Thompson<sup>2</sup>, Jason S. Simon<sup>3</sup>, Kevin V. Shianna<sup>1</sup>, Thomas J. Urban<sup>1</sup>, Erin L. Heinzen<sup>1</sup>, Ping Qiu<sup>3</sup>, Arthur H. Bertelsen<sup>3</sup>, Andrew J. Muir<sup>2</sup>, Mark Sulkowski<sup>4</sup>, John G. McHutchison<sup>2</sup> & David B. Goldstein<sup>1</sup> Nature 461: 399,

- rs12979860, 3 kb
   upstream of *IL28B*,
   encoding
   Interferon λ3
- Response to treatment with PEG-IFN-α-2a or 2b
- OR for SVR ~7 for CC vs, CT or TT





Sir Luke Fildes, The Doctor, 1891

## Thanks for your attention!

The NEW ENGLAND JOURNAL of MEDICINE

**REVIEW ARTICLE** 

#### **GENOMIC MEDICINE**

W. Gregory Feero, M.D., Ph.D., and Alan E. Guttmacher, M.D., Editors

## Genomics of Cardiovascular Disease


Christopher J. O'Donnell, M.D., and Elizabeth G. Nabel, M.D. NEJM 365: 22, 2011

dvalle@jhmi.edu

# Thanks and Acknowledgements

- Barton Childs
- Victor McKusick

 Colleagues in the IGM and throughout Johns Hopkin



- Childs B, Genetic Medicine: A logic of disease, 1999
- Childs & Valle, Ann Rev Hu Genet 1: 1, 2000
- Childs et al, Ann Rev Gen Hu Genet 6: 313, 2005

Valle\_Jan\_2011